ReviewFrontiers in aging2026
Research progress on Alzheimer's disease vaccines: from Aβ-targeted approaches to clinical translation.
Review in Frontiers in aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by progressive cognitive impairment, with the β-amyloid protein (Aβ) aggregation as a core pathological driver. As global aging intensifies, AD poses a severe public health burden, highlighting the urgency of developing effective immunotherapies. This review aims to systematically summarize the research progress of Aβ-targeted AD vaccines, from first-generation approaches to next-generation strategies, and discuss key challenges and future directions for clinical translation. Methods: A comprehensive literature search was conducted across PubMed, Web of Science, the Cochrane Library, EMBASE, and Google Scholar up to 14 November 2025. Relevant studies were selected using predefined eligibility criteria, focusing on Aβ-targeted AD vaccines' development, mechanisms, preclinical efficacy, and clinical outcomes. Review articles and meta-analyses were included, while case reports and non-Aβ-targeted studies were excluded. Data extraction and synthesis focused on vaccine strategies, immune mechanisms, and translational challenges. Results: First-generation Aβ vaccine (e.g., AN-1792) showed preclinical promise but failed clinically due to autoimmune complications. Next-generation vaccines, including peptide/epitope vaccines, DNA vaccines, viral vector vaccines, and protein self-assembling vaccines, have been developed to induce protective Th2-biased immune responses while avoiding harmful T-cell reactions. Preclinical studies demonstrate reduced Aβ deposition and improved cognitive function, with several candidates advancing to clinical trials showing favorable safety and immunogenicity. Key mechanisms include Fc receptor-mediated phagocytosis, antibody-mediated fibril disaggregation, and the peripheral Aβ sink effect. Conclusion: Aβ-targeted AD vaccines have evolved toward safer and more effective designs, with multiple strategies showing translational potential. Challenges remain, including blood-brain barrier (BBB) penetration, immune response modulation, and defining optimal therapeutic time windows. Future research should focus on personalized vaccines, combination therapies, and novel antigen delivery platforms to fully realize the clinical potential of AD immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.